XBCD identified five true positives and 166 true negatives, yielding a sensitivity of 71.4%, specificity of 88.8%, and a negative predictive value of 98.8%. In this low-prevalence setting, XBCD demonstrated potential as a triage tool to reduce the number of procedures and support earlier BC detection, although findings are limited by the small number of cancer cases.

9 days ago

Journal

Xpert® Bladder Cancer Monitor

UroDetect III: Study on Risk Assessment for Patients With Microscopic Hematuria (Non-Visible Blood in Urine) Using a Urine Marker Test (clinicaltrials.gov)

P=N/A, N=1475, Not yet recruiting, Christian Bolenz

1 month ago

New trial

Xpert® Bladder Cancer Monitor

2ms

Diagnostic and Prognostic Implications of FGFR3, TP53 Mutation and Urinary Biomarkers in Urothelial Carcinoma in Pakistani Cohort. (PubMed, J Clin Med)

The integrated approach of IHC with genotyping could improve risk stratification and guide personalized management strategies. Moreover, as cytology is less sensitive to diagnose UC, especially low-grade tumours, Xpert BCM can be used as a promising diagnostic test for both primary and recurrent BC settings.

2 months ago

Journal

TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3)

TP53 mutation • FGFR3 mutation

Xpert® Bladder Cancer Monitor

2ms

The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial (clinicaltrials.gov)

P2, N=262, Not yet recruiting, Chiti Arturo

2 months ago

New P2 trial • Liquid biopsy

Bladder EpiCheck® • Xpert® Bladder Cancer Monitor

TEST:Xpert® Bladder Cancer Monitor

News

TEST:
Xpert® Bladder Cancer Monitor